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Abstract 
Background 
Health authorities in numerous countries recommend periconceptional folic acid 
supplementation to prevent neural tube defects. The objective of this study was to examine 
the association of dietary folate intake and folic acid supplementation during different periods 
of pregnancy with the risk of spontaneous preterm delivery (PTD). 
Methods 
The Norwegian Mother and Child Cohort Study is a population-based prospective cohort 
study. A total of 66,014 women with singleton pregnancies resulting in live births in 2002–
2009 were included. Folic acid supplementation was self-reported from 26 weeks before 
pregnancy until pregnancy week 24. At gestational week 22, the women completed a food 
frequency questionnaire, which allowed the calculation of their average total folate intake 
from foods and supplements for the first 4–5 months of pregnancy. Spontaneous PTD was 
defined as the spontaneous onset of delivery between weeks 22+0 and 36+6 (n = 1,755). 
Results 
The median total folate intake was 313 µg/d (interquartile range IQR 167–558) in the overall 
population and 530 µg/d (IQR 355–636) in the supplement users. Eighty-five percent 
reported any folic acid supplementation from <8 weeks before to 24 weeks after conception 
while only 44% initiated folic acid supplementation before pregnancy. Cox regression 
analysis showed that the amount of dietary folate intake (hazard ratio HR 1.00; confidence 
interval 95% CI 0.61-1.65) and supplemental folate intake (HR 1.00; CI 1.00-1.00) was not 
significantly associated with the risk of PTD. The initiation of folic acid supplementation 
more than 8 weeks before conception was associated with an increased risk for spontaneous 
PTD (HR 1.18; CI 1.05-1.32) compared to no folic acid supplementation preconception. 
There was no significant association with PTD when supplementation was initiated within 8 
weeks preconception (HR 0.99; CI 0.87-1.13). All analyses were adjusted for maternal 
characteristics and socioeconomic, health and dietary variables. 
Conclusions 
Our findings do not support a protective effect of dietary folate intake or folic acid 
supplementation on spontaneous PTD. Preconceptional folic acid supplementation starting 
more than 8 weeks before conception was associated with an increased risk of spontaneous 
PTD. These results require further investigation before discussing an expansion of folic acid 
supplementation guidelines. 
Keywords 
Pregnancy, Preterm delivery, Preterm birth, Gestational length, Folate, Folic acid 
supplementation 
Background 
Folate is a B-vitamin essential for one-carbon metabolism and takes part in amino acid 
metabolism as well as DNA synthesis, repair and methylation [1,2]. Women are especially 
susceptible to folate deficiency during pregnancy, which is a period of rapid fetal growth, 
organ differentiation and high rates of cell division [1,3,4]. Since the 1950s, folic acid 
supplementation has been known to prevent megaloblastic anemia during pregnancy [5]. In 
the 1990s, large randomized trials demonstrated that periconceptional folic acid 
supplementation can prevent neural tube defects (NTDs) in the newborn infant [6-8]. Today, 
national health authorities in many countries recommend periconceptional folic acid 
supplementation, and some countries have introduced mandatory folate fortification of foods 
[1,3,4,9,10]. In Norway, folic acid supplementation of 400 µg/d is recommended from the 
time of planning a pregnancy to gestational week 12 [2,11], as is a daily folate intake of 500 
µg/d. This is in line with the Nordic Nutrition Recommendations [2]. 
Maternal folate status has also been associated with other adverse pregnancy outcomes such 
as preeclampsia, malformations such as orofacial clefts, spontaneous abortion, fetal death, 
fetal growth restriction and preterm delivery (PTD), although these results still remain 
inconclusive [1]. 
PTD, defined by the World Health Organization (WHO) as birth occurring before 37 weeks 
of gestation, is considered a major global health problem and is strongly associated with 
neonatal mortality as well as short- and long-term morbidity [12-14]. Spontaneous PTD is a 
common, complex condition with a prevalence of approximately 7% in the Norwegian 
population [15]. However, the effect of any single environmental factor is difficult to 
measure without large-scale studies [15]. Modern obstetrics are still not able to predict, 
prevent or treat PTD [16]. Progesterone substitution, the only promising intervention 
identified to date, has been shown to reduce the chance of spontaneous PTD in high-risk 
pregnancies, but such cases account for only a small proportion of all pregnancies [17,18]. 
In the past decade, some observational studies have found that folic acid supplementation 
reduces the risk of PTD [19-22]. In some studies, this effect has been documented with an 
extended folic acid supplementation scheme or dosage compared with schemes based on 
NTD prevention, e.g., preconceptional folic acid supplementation for one year or longer [21] 
or third-trimester folic acid supplementation [22]. A study based on the previous Cochrane 
review and data of one of the largest randomized controlled trials (RCT), a recent meta-
analysis of all published RCTs, as well as the recent Cochrane review based on 3 controlled 
trials could not confirm any effect of the maternal folate status on the gestational length or the 
risk of spontaneous PTD [23-25]. The comparability and generalizability of these earlier 
studies, which focused on the association of folate status and folic acid supplementation with 
pregnancy outcome, is limited because folic acid supplementation was assessed without 
considering other folate sources, the study populations had different levels of dietary folate 
intake, inadequate sample sizes, limited adjustment for important confounders, and/or 
retrospective study designs with folate data collection only after delivery [1,4]. Although 
PTD is a heterogeneous pregnancy outcome with different etiologies (early vs. late or 
iatrogenic vs. spontaneous), previous studies have mostly treated PTD as one entity, 
obscuring the differences in risk among PTD subtypes [26,27]. 
The Norwegian Mother and Child Cohort Study (MoBa) can meet a number of these 
challenges in study design, a requirement for addressing the inconsistencies in the field. 
MoBa includes more than 106,000 pregnancies, enabling the investigation of common 
complex pregnancy outcomes such as PTD. A detailed prospective assessment of folic acid 
supplementation starting from 6 months before conception throughout pregnancy, data 
regarding dietary folate intake and comprehensive information about lifestyle habits, health 
and socioeconomic status provide a unique opportunity to study the association between 
folate intake and PTD. For example, the effect of folic acid supplementation can be compared 
between women with low and high dietary folate intakes. By taking into account the amount 
of dietary folate and folic acid supplementation during different periods of pregnancy, it 
might be possible to define the folic acid supplementation scheme most likely to affect PTD 
risk. 
The aim of this study was to examine the association of maternal folate intake from both 
supplemental and dietary sources with the risk of spontaneous PTD, with sub-analyses of 
early and late spontaneous PTD. The association of folic acid supplementation with PTD was 
studied in a stratified sample of women with low and high dietary folate intakes (</≥170 
µg/d). 
Methods 
Study population 
The dataset is part of the MoBa cohort, initiated by and maintained at the Norwegian Institute 
of Public Health [15]. In brief, MoBa is a nation-wide pregnancy cohort that has included 
more than 106,000 pregnancies in the years from 1999 to 2009. The women were recruited 
through a postal invitation in connection with a routine ultrasound examination offered to all 
pregnant women in Norway approximately 17 weeks of gestation. Overall, 38.5% of the 
invited women participated. They were asked to fill in questionnaires focused on overall 
health status, lifestyle behavior and diet at gestational weeks 15–17 (Q1) and 30 (Q3). At 
week 22, they completed a food frequency questionnaire (FFQ). All questionnaires are 
available from the homepage of the Norwegian Institute of Public Health [28]. The present 
study used data from version 6 of the quality-assured data files made available for research in 
2011. The MoBa database is linked to pregnancy and birth records from the Medical Birth 
Registry of Norway (MBRN) [29]. Informed written consent was obtained from each 
participant. The Regional Committee for Medical Research and the Norwegian Data 
Inspectorate approved the study. 
Of 106,707 pregnancies included in the MoBa version 6, 103,921 pregnancies resulted in 
live-born singletons. Complete data for all 3 questionnaires including information about 
folate intake were available for 81,329 pregnancies. Women reporting improbable energy 
intakes of <4.5 MJ or >20 MJ were excluded [30], leaving 80,056 pregnancies. After 
exclusion of women with prepregnancy diabetes mellitus, chronic hypertension, chronic 
kidney disease, epilepsia, rheumatoid arthritis and those that underwent in-vitro fertilization, 
76,298 pregnancies were included in the study. Pregnancies with a gestational length of <22+0 
or >42+6 weeks were excluded from further analysis, leaving 75,873 remaining. If a woman 
participated for more than one pregnancy, only her first pregnancy enrolled was included, 
leaving 66,014 pregnancies for analyses. 
Outcome 
The gestational age in days was determined with a second-trimester ultrasound in 98.4% of 
the pregnancies and was based on the last menstrual period in the remaining cases. 
Spontaneous PTD was defined as birth after preterm labor or pre-labor rupture of the 
membranes between 22+0 and 36+6 weeks. To distinguish between early and late spontaneous 
PTDs, we used the following gestational time-windows: early (22+0-33+6) and late (34+0-36+6) 
PTD. 
Exposure 
Amount of folate intake 
The amount of folate intake was calculated from the MoBa FFQ, a semi-quantitative 
questionnaire designed to yield information regarding the dietary habits and intake of dietary 
supplements during the first 5 months of pregnancy. The questionnaire data were read 
optically, and the nutrient and energy intakes were calculated using FoodCalc [31] and the 
Norwegian Food Composition Table [32]. For the calculation of nutrients in the dietary 
supplements, an Access database containing the nutrient values of more than 1,000 dietary 
supplements was created and continuously updated using Microsoft Office 2003 software. 
Dietary supplements commonly sold in Norway were registered based on information 
provided by the respective manufacturer, whereas nutritional information concerning dietary 
supplements bought from the Internet or abroad were obtained from the manufacturer’s or 
supplier’s homepage. A data program connected to the Access database read all food 
supplements recorded by the MoBa participants. The process of extracting dietary and 
supplement data is described in detail elsewhere [33,34]. 
Dietary folate was defined as 60% of the reported folate intake from foods, as only 
approximately 60% may be biologically accessible in comparison to that from the synthetic 
folic acid in supplements [1,3]. The total folate intake was thus calculated as supplemental 
folic acid +0.6 × folate intake from foods. 
The daily folate intake was also categorized into 4 groups: <170 µg/d (corresponding to the 
earlier WHO recommendation for all women to prevent anemia [10,35]), 170–500 µg/d 
(corresponding to the current Nordic Nutrition Recommendations for pregnant women for the 
prevention of NTDs [2]), 500–1000 µg/d (corresponding to the tolerable upper limit for folic 
acid [2]) and >1000 µg/d. 
Timing of folic acid supplementation 
The women reported their folic acid supplement use from 26 weeks before conception until 
gestational week 24 in 4-week intervals, including the frequency of supplementation. A 
woman was defined as a folic acid supplement user if she reported any use of folic acid – 
containing supplements for more than once a week in a registered 4-week period. Folic acid 
may be consumed either in the form of a folic acid supplement alone or as part of 
multivitamins. The most commonly used folic acid supplements for pregnant women in 
Norway contain 400 µg of folic acid, while the most commonly used multivitamin 
supplements contain 200 µg of folic acid. For this study, the start of folic acid 
supplementation was categorized as start during 26–9 weeks before conception, start during 
8–0 weeks before conception, and no preconceptional folic acid supplementation. 
Covariates 
Covariates were chosen a priori based on the available literature. Information regarding the 
maternal age at delivery as well as the child’s sex is available from the MBRN. Parity was 
based on data from both the MoBa and MBRN and based on the number of previous 
pregnancies of ≥22+0 weeks’ duration. Marital status was defined as either married/cohabitant 
or not. The self-reported pre-pregnancy heights and weights were used to calculate the pre-
pregnancy body mass index (BMI) and were grouped according to the WHO classification as 
underweight (<18.5 kg/m2), normal (18.5-24.9 kg/m2), overweight (25.0-29.9 kg/m2) and 
obese (≥30.0 kg/m2). Maternal education was categorized as ≤12 y, 13–16 y and ≥17 y. The 
history of previous PTD before 37+0 weeks of gestation, and the history of spontaneous 
abortion, as registered in the MBRN, were taken into account as dichotomous variables in 
regression models. Women reported smoking habits during pregnancy in Q1 and were 
categorized as non-smokers, occasional or daily smokers. The alcohol intake from different 
sources was self-reported in the FFQ (glasses/d, week or month) and calculated as g/d. The 
household income was classified as both the participant and her partner having <300,000 
Norwegian Kroner (NOK)/y, as either the participant or her partner having ≥300,000 NOK/y 
or as the participant and her partner both having ≥300,000 NOK/y. Vitamin A 
supplementation was registered and categorized in the same manner as described for folic 
acid. These variables were used as a proxy for multivitamin supplementation, as there are no 
products on the Norwegian market containing vitamin A alone, and vitamin A is part of all 
common multivitamin preparations. In MoBa more than 99% of the participants are of 
Caucasian ethnicity; hence, ethnicity was not a relevant confounder. 
Statistical methods 
All statistical analyses were performed using IBM SPSS Statistics 22 and R 2.13.1 software. 
Total dietary folate intake from foods and supplements (median (IQR)) in relation to the 
maternal characteristics was studied with the Kruskal-Wallis test. The start of folic acid 
supplementation in relation to the maternal characteristics was studied with Pearson’s chi-
squared test. The association of total dietary folate intake and spontaneous PTD was 
estimated as a hazard ratio (HR) with a 95% confidence interval (CI) by using Cox regression 
both in an unadjusted model and adjusted for the above-mentioned covariates. In these 
models, the event was defined as a spontaneous PTD; all iatrogenic deliveries and deliveries 
after the preterm (≥37+0 weeks) or early preterm (≥34+0 weeks) period were censored. The 
proportional hazards assumption was investigated by testing and inspecting scaled 
Schoenfeld residuals using R function cox.zph [36]. Statistical significance was assumed for 
2-sided p-values of <0.05. 
Results 
Folate intake and folic acid supplementation in the study population 
The median total dietary folate intake during the first five months of pregnancy and start of 
folic acid supplementation according to maternal characteristics are presented in Table 1. 
Dietary folate intake was highest in women aged 25–29 years, in women who did not smoke, 
had low or normal BMI (18.5-24.9 kg/m2), who were having their first child, were 
married/cohabitant, who had higher education levels and family incomes. Women having 
experienced PTD had significantly lower total folate intakes. While women with a history of 
spontaneous abortion had more often started folic acid supplementation early, no comparable 
pattern in women with a history of PTD was found (Table 1). 
Table 1 Folate variables and maternal characteristics 
    Total folate intake (µg/d) Initiation of preconceptional folic acid supplementation, n (%) 
  n (%) Median (IQR) p1 >8 w 0-8 w no p2 
Total  66014 (100) 313 (167–558)  16023 (24) 12877 (20) 37114 (56)  
 <25 7561 (12) 258 (154–528)  849 (11) 942 (13) 5770 (76)  
Maternal age 25-29 22672 (34) 324 (170–562) <0.0001 5121 (23) 4821 (21) 12730 (56) <0.0001 
in years 30-34 27993 (42) 319 (168–562)  7726 (28) 5894 (21) 14373 (51)  
 >34 7788 (12) 315 (170–562)  2327 (30) 1220 (16) 4241 (55)  
Pre- <18.5 1931 (3) 343 (179–575)  432 (22) 351 (18) 1148 (60)  
pregnancy 18.5-24.9 42611 (65) 328 (173–566) <0.0001 10773 (25) 8637 (20) 23201 (54) <0.0001 
BMI in 25-30 13839 (21) 289 (160–548)  3228 (23) 2651 (19) 7960 (58)  
kg/m2 ≥30 5970 (9) 268 (151–533)  1305 (22) 953 (16) 3712 (62)  
 missing 1663 (3) 250 (156–517)  285 (17) 285 (17) 1093 (66)  
 0 34825 (53) 355 (180–580)  9324 (27) 6480 (19) 19021 (55)  
 1 20028 (30) 281 (159–545) <0.0001 4528 (23) 4531 (23) 10969 (55) <0.0001 
Parity 2 9005 (14) 245 (156–517)  1787 (20) 1570 (17) 5648 (63)  
 3+ 2101 (3) 224 (149–451)  370 (18) 285 (14) 1446 (69)  
 missing 55 (0.1) 353 (166–566)  14 (26) 11 (20) 30 (55)  
Marital yes 63518 (96) 315 (168–559) <0.0001 15714 (25) 12661 (20) 35143 (55) <0.0001 
status no 2496 (4) 266 (158–531)  309 (12) 216 (9) 1971 (79)  
Maternal <13 20198 (31) 244 (150–515)  3263 (16) 2886 (14) 14049 (70)  
education 13 - 16 27606 (42) 338 (172–567) <0.0001 7118 (26) 5849 (21) 14639 (53) <0.0001 
in >16 16838 (26) 374 (187–581)  5340 (32) 3916 (23) 7582 (45)  
years missing 1372 (2) 283 (161–550)  302 (22) 226 (17) 844 (62)  
History of no 63698 (97) 314 (168–559) <0.0001 15510 (24) 12411 (20) 35777 (56) 0.047 
preterm yes 2205 (3) 276 (158–539)  487 (22) 435 (20) 1283 (58)  
delivery missing 111 (0.2) 297 (175–560)  26 (23) 31 (28) 54 (49)  
History of no 45164 (68) 315 (168–559) 0.15 10262 (23) 8930 (20) 25972 (58) <0.0001 
abortion yes 12418 (19) 308 (166–558)  3932 (32) 2296 (19) 6190 (50)  
 missing 8432 (13) 308 (165–557)  1829 (22) 1651 (20) 4952 (59)  
 never 60452 (92) 322 (170–563)  15339 (25) 12271 (20) 32842 (54)  
Smoking occasionally 1741 (3) 261 (158–511) <0.0001 243 (14) 226 (13) 1272 (73) <0.0001 
habits daily 3449 (5) 217 (141–485)  378 (11) 316 (9) 2755 (80)  
 missing 372 (0.6) 236 (148–500)  63 (17) 64 (17) 245 (66)  
Alcohol no alcohol 58659 (89) 314 (167–559)  14448 (25) 11528 (20) 32683 (56)  
consumption <0.5 6155 (9) 311 (170–556) 0.21 1326 (22) 1164 (19) 3665 (60) <0.0001 
in units/week ≥0.5 1200 (2) 286 (167–531)  249 (21) 185 (15) 766 (64)  
Partners with 0 18364 (28) 279 (161–540) <0.0001 3176 (17) 2904 (16) 12284 (67)  
income of 1 27212 (41) 309 (166–557) 6460 (24) 5451 (20) 15301 (56) <0.0001 
>300,000 2 18608 (28) 360 (178–579) 6130 (33) 4247 (23) 8231 (44)  
NOK/year missing 1830 (3) 264 (158–533)  257 (14) 275 (15) 1298 (71)  
Baby’s male 33791 (51) 309 (166–558) 0.07 8190 (24) 6525 (19) 19076 (57) 0.4 
sex female 32223 (49) 316 (169–559)  7833 (24) 6352 (20) 18038 (56)  
Tertiles of 1 22005 (33) 272 (127–525)  5577 (25) 4338 (20) 12090 (55)  
energy intake 2 22005 (33) 317 (166–561) <0.0001 5511 (25) 4485 (20) 12009 (55) <0.0001 
in MJ 3 22004 (33) 344 (211–600)  4935 (22) 4054 (18) 13015 (59)  
Amount of total daily folate intake (FFQ data) and initiation of preconceptional folic acid supplementation (Q1 data) according to maternal 
characteristics, from 66,014 participants in the Norwegian Mother and Child Cohort Study (2002 – 2009). 
1
 p-value, estimated with Kruskal-Wallis test. 
2
 p-value, estimated with Pearson’s chi-squared test. 
Figure 1 illustrates the pattern of folic acid supplementation in the study population compared 
to vitamin A supplementation (as a proxy for multivitamin consumption) over the course of 
pregnancy. 85% of all women in the study reported folic acid supplementation at some point 
before and/or during pregnancy (Figure 1). While 44% initiated folic acid supplementation 
prior to conception, nearly 77% used supplements containing folic acid in the first trimester 
with decreasing use towards the end of pregnancy. At the same time, vitamin A 
supplementation was much more stable over the whole length of the pregnancy. The amount 
of folic acid supplementation varied considerably, with only 2 women consuming folic acid 
amounts of >5000 µg/d, 610 consuming >1000 µg/d (1%), 6,834 consuming >500 µg/d 
(10%), 10,681 consuming >400 µg/d (16%), 27,183 consuming >200 µg/d (41%) and 34,234 
consuming >100 µg/d (52%). Among supplement users, the median daily folic acid 
supplementation was 400 µg/d (interquartile range IQR 200–429). As presented in Table 2, 
folic acid from supplements was the main folate source in supplement users, while the main 
source was dietary folate in the whole population. There is no mandatory folate fortification 
of foods in Norway, and only 3% (n = 1,946, not adjusted for bioavailability) of the study 
population reached the Nordic Nutrition Recommendation of 500 µg/d with their dietary 
folate intake. Of the study participants, 44% (n = 28,959, not adjusted for bioavailability) 
achieved the recommended levels with their total folate intake. 
Figure 1 Prevalence of folic acid and vitamin A supplementation during pregnancy. 
Prevalence of folic acid and vitamin A supplementation during pregnancy (Q1 and Q3 data) 
in women with spontaneous non-preterm (37+0-42+6 weeks, n = 51,141) or preterm delivery 
(22+0-36+6 weeks, n = 1,755) among 66,014 participants in the Norwegian Mother and Child 
Cohort Study (2002 – 2009). 
Table 2 Folate intake from diet and supplements 
 All Spontaneous delivery 37+0- 42+6 Spontaneous PTD 
22+0-36+6 
Folate (µg/d) Median IQR Median IQR Median IQR 
All women n = 66014 n = 51141 n = 1755 
Diet 157 (126–196) 157 (126–196) 157 (126–196) 
Supplements 143 (0–400) 143 (0–400) 171 (0–400) 
Total intake 313 (167–558) 312 (167–558) 322 (167–568) 
Supplement users n = 39600 n = 30684 n = 1056 
Diet 158 (127–197) 158 (127–197) 159 (128–198) 
Supplements 400 (200–429) 400 (200–429) 400 (200–457) 
Total intake 530 (355–636) 530 (355–634) 541 (369–651) 
Folic acid supplementation, dietary and total folate intake during the first half of pregnancy 
(FFQ data) for all 66,014 participants, as well as in folic acid supplement users (n = 39,600), 
from the Norwegian Mother and Child Cohort Study (2002–2009). 
Folate intake from different sources and risk for spontaneous PTD 
The median gestational age in this study population was 281 days (IQR 274–287), with 2,906 
(4%) cases of PTD and 1,755 cases of spontaneous PTD (2.7%). Of these, 334 babies were 
delivered before 34+0 weeks of gestation (0.5%). Thus the overall PTD rate in our study 
population is approximately half of the PTD rate in the general Norwegian population as we 
excluded risk-pregnancies due to maternal disease as well as multiple gestations and 
intrauterine death. 
There was no significant association between the amount of folate intake from the diet or 
supplements with the risk of spontaneous PTD (Table 3). As 95% CIs were very narrow, we 
performed the same analysis in deciles of total folate intake as well with a categorized 
variable according to deciles of total folate intake with no change of results (data not shown). 
Likewise, no association was found when the total folate intake was categorized according to 
the former WHO recommendation for women (>170 µg/d), the current Nordic Nutrition 
Recommendations for pregnant women (>500 µg/d) and the tolerable upper limit (for folic 
acid supplementation: <1000 µg/d) (Additional file 1: Table S1). Cox regression for the sub-
groups of early and late spontaneous PTD did not reveal any significant associations between 
the folate intake and pregnancy outcome (not shown). Testing the proportional hazards 
assumptions revealed a slight misfit for the parity variable. Therefore all analyses were also 
run with stratified Cox regression using parity as strata. The changes from the unstratified 
analyses were however marginal and did not change any pattern or results. 
Table 3 Folate intake from different sources and risk of spontaneous preterm delivery 
(PTD) 
 Unadjusted Adjusted2 
Folate (µg/d) HR1 (95% CI) p HR1 (95% CI) p 
Diet 1.00 (0.61; 1.65) 0.61 1.00 (0.61; 1.65) 0.54 
Supplements 1.00 (1.00; 1.00) 0.25 1.00 (1.00; 1.00) 0.53 
Total intake 1.00 (1.00; 1.00) 0.22 1.00 (1.00; 1.00) 0.46 
Amount of folic acid supplementation, dietary and total folate intake (FFQ data) and hazard 
ratios for spontaneous PTD (22+0-36+6 weeks, n = 1,755). Cox regression for 66,014 
participants in the Norwegian Mother and Child Cohort Study (2002–2009). Iatrogenic 
deliveries have been censored in the regression model. 
1
 HR per 500 µg extra folate/d. 
2
 Cox regression, adjusted for maternal age, prepregnancy BMI, parity, history of PTD and 
spontaneous abortion, child’s sex, smoking habits and alcohol consumption during 
pregnancy, maternal education, marital status, household income, energy intake. Mutual 
adjustment for dietary and supplemental folate intake. 
Initiation of folic acid supplementation and risk for spontaneous PTD 
The initiation of folic acid supplementation more than 8 weeks preconception was associated 
with increased risk of spontaneous PTD overall also after adjusting for potential confounders 
(Table 4 and Additional file 2: Figure S1a; hazard ratio HR 1.19; confidence interval CI 1.05-
1.34). The initiation of supplementation more than 8 weeks before conception was 
significantly associated with early (<34+0 weeks) but not late spontaneous PTD (Additional 
file 3: Figure S1b). After stratification for the total dietary folate intake from foods, the 
initiation of folic acid supplementation more than 8 weeks before conception was 
significantly associated with an increased risk of spontaneous PTD for those women with low 
dietary folate intakes (adjusted HR 1.18; 95% CI 1.05-1.32). The same association was found 
in the subgroup of early (adjusted HR 1.60; 95% CI 1.24-2.10) but not late spontaneous PTD 
(Additional file 4: Table S2). 
Table 4 Initiation of preconceptional folic acid supplementation and risk of spontaneous preterm delivery (sPTD) 
sPTD Initiation of folic acid supplementation  Unadjusted Adjusted1 Adjusted2 
  n HR (CI) p HR (CI) p HR (CI) p 
All No 964 1   1   1   
 0-8 w preconception 313 0.93 (0.82; 1.06) 0.28 0.99 (0.87; 1.13) 0.89 1.01 (0.88; 1.16) 0.88 
 >8 w preconception 478 1.15 (1.03; 1.29) 0.01 1.18 (1.05; 1.32) 0.005 1.20 (1.06; 1.36) 0.004 
Early No 169 1   1   1   
 0-8 w preconception 57 0.97 (0.72; 1.31) 0.84 1.07 (0.79; 1.45) 0.67 1.04 (0.76; 1.43) 0.81 
 >8 w preconception 108 1.48 (1.16; 1.89) 0.001 1.60 (1.24; 2.06) <0.001 1.55 (1.18; 2.05) 0.002 
Late No 795 1   1   1   
 0-8 w preconception 256 0.92 (0.80; 1.06) 0.23 0.97 (0.84; 1.11) 0.63 0.99 (0.86; 1.15) 0.93 
 >8 w preconception 370 1.08 (0.96; 1.22) 0.22 1.09 (0.96; 1.24) 0.19 1.12 (0.98; 1.29) 0.11 
Initiation of preconceptional folic acid supplementation (Q1 data) and hazard ratios (HR) for spontaneous PTD (n = 1,755 for 22+0-36+6 weeks, n 
= 334 for early (22+0-33+6 weeks), n = 1,421 for late (34+0-36+6 weeks)). Cox regression for 66,014 participants in the Norwegian Mother and 
Child Cohort Study (2002 – 2009). Iatrogenic deliveries have been censored in the regression model. 
1
 Cox regression, adjusted for maternal age, prepregnancy BMI, parity, history of PTD and spontaneous abortion, child’s sex, smoking habits 
and alcohol consumption during pregnancy, maternal education, marital status, household income, energy intake and dietary folate intake. 
2
 Adjustment as above as well as for first-trimester folic acid supplementation and preconceptional and first-trimester vitamin A 
supplementation. 
A history of earlier adverse pregnancy outcome could be a motive for the early initiation of 
folic acid supplementation in subsequent pregnancies. However, the analysis of the subgroup 
of women being pregnant the first time (n = 25,281, 38%) showed the same overall results for 
the early initiation of folic acid supplementation (n = 815 cases of spontaneous PTD, adjusted 
HR 1.30; CI 1.10-1.53). 
The early initiation of folic acid supplementation could characterize women that planned a 
pregnancy but did not become pregnant during the first months, thus including a subgroup of 
sub-fertile women [37]. In MoBa, the women were asked to report the number of months 
with regular intercourse without contraception before becoming pregnant, and these data 
were classified as follows: <1 month (n = 13,128, 20%), 1–2 months (n = 15,142, 23%) and 
>2 months (n = 22,702, 34%). Stratification for this variable still showed increased HRs for 
the early initiation of folic acid supplementation in the subgroup that became pregnant within 
the first month (adjusted HR 1.58; CI 1.17-2.12), the HRs for the small subgroup with early 
PTD (n = 68) was not significant (adjusted HR 1.78; CI 0.98-3.23). 
Timing of folic acid supplementation and risk for spontaneous PTD 
The time of folic acid supplementation was represented by four variables corresponding to 
the following periods: 26–9 weeks before conception, 0–8 weeks before conception, first 
trimester and second trimester. If the Cox regression included all of the confounders and the 
outcome of spontaneous PTD was analyzed, the prediction of the model improved after 
introducing all four folic acid supplementation variables (p = 0.006). Folic acid supplement 
use more than 8 weeks preconception was associated with an increased HR for spontaneous 
PTD, even after adjusting for the supplementation at all other time points (Table 5). 
Table 5 Timing of folic acid supplementation and risk of spontaneous preterm delivery (PTD) 
 Time of folic acid supplementation sPTD Unadjusted Adjusted1 
  n HR (CI) p HR (CI) p 
All >8 w preconception 478 1.17 (1.06; 1.30) 0.003 1.17 (1.04; 1.32) 0.01 
 0-8 w preconception 648 1.01 (0.92; 1.12) 0.80 1.01 (0.90; 1.13) 0.84 
 1st trimester 1326 0.94 (0.84; 1.05) 0.26 0.89 (0.79; 1.00) 0.05 
 2nd trimester 869 1.10 (1.00; 1.21) 0.04 1.08 (0.98; 1.19) 0.11 
Early >8 w preconception 108 1.49 (1.19; 1.88) 0.001 1.51 (1.16; 1.97) 0.002 
 0-8 w preconception 133 1.15 (0.92; 1.43) 0.23 1.03 (0.80; 1.34) 0.81 
 1st trimester 262 1.11 (0.85; 1.44) 0.45 0.99 (0.74; 1.32) 0.95 
 2nd trimester 173 1.21 (0.97; 1.49) 0.09 1.12 (0.89; 1.39) 0.34 
Late >8 w preconception 370 1.10 (0.98; 1.24) 0.10 1.10 (0.97; 1.26) 0.15 
 0-8 w preconception 515 0.98 (0.88; 1.09) 0.69 1.00 (0.88; 1.13) 0.94 
 1st trimester 1064 0.91 (0.81; 1.03) 0.13 0.87 (0.76; 1.00) 0.04 
 2nd trimester 696 1.08 (0.98; 1.20) 0.13 1.08 (0.97; 1.20) 0.17 
Folic acid supplementation at different times (Q1 and Q3 data) and hazard ratios (HR) for spontaneous PTD (n = 1.755 for 22+0-36+6 weeks, n = 
334 for early (22+0-33+6 weeks), n = 1,421 for late (34+0-36+6 weeks)) as compared to no intake at that time of pregnancy. Cox regression for 
66,014 participants in the Norwegian Mother and Child Cohort Study (2002 – 2009). Iatrogenic deliveries have been censored in the regression 
model. 
1
 Cox regression, adjusted for maternal age, prepregnancy BMI, parity, history of PTD and spontaneous abortion, child’s sex, smoking habits 
and alcohol consumption during pregnancy, maternal education, marital status, household income, energy intake and dietary folate intake. 
Mutual adjustment for folic acid supplementation at other time points.
 Discussion 
In this large prospective national birth cohort, we did not find any statistically significant 
association of the amount of folate intake from the diet or supplements with spontaneous 
PTD. Folic acid supplementation starting more than 8 weeks before conception was 
associated with an increased HR for spontaneous PTD. 
When interpreting the results, the selection of the study population has to be kept in mind: 
risk-pregnancies due to maternal disease and multiple gestations have been excluded from the 
analysis so that we do not know if there is any association of the amount of folate intake from 
diet or supplements with spontaneous PTD in the excluded high risk pregnancies. 
Our results, demonstrating no significant protective effect of the maternal folate intake or 
folic acid supplementation on the spontaneous PTD risk, support a number of earlier 
observational studies [38-43] and RCTs [6,44,45]. A reanalysis of a previous Cochrane 
review, and one of the largest RCTs, a recent meta-analysis of all RCTs published to date as 
well as the most recent Cochrane review based on 3 available trials, showed no association of 
the maternal folate status with the gestational length or the risk of PTD [23-25]. Extensive 
supplementation with multivitamins with a major folic acid component was associated with 
an increased risk of PTD in a study by Alwan et al. [38]. When analyzing data from the US 
National Birth Defects Study, Shaw et al. found a lower risk of PTD for women starting 
supplementation during pregnancy as compared to preconceptional supplementation start 
[43]. 
However, results are conflicting as summarized in the review by Mantovani et al. [27]. A 
protective effect of folic acid supplementation was supported by a modest reduction in the 
PTD rate after the introduction of folate fortification of foods [9]. Some recent observational 
studies have found that folic acid supplementation reduces the risk of PTD [20-22]. In some 
cases, this association was found for preconceptional folic acid supplementation for 1 year or 
longer [21] or third-trimester folic acid supplementation [22], raising questions about 
extended supplementation schemes compared to the NTD prevention scheme. Folic acid 
supplementation more than a 1 year before becoming pregnant is not registered in MoBa, but 
data for the earliest interval (26–9 weeks before conception) suggest an adverse effect of 
longtime folic acid supplementation on the risk of spontaneous PTD. Though third trimester 
folic acid supplementation is registered in MoBa, we chose to not include third trimester 
supplementation as the early PTDs already have occurred at different time points during this 
period, so that we were not able to retrace the findings by Czeizel et al. [22]. 
One possible explanation for these conflicting results could be the dosage of folic acid. While 
most of the studies finding an association with gestational length or PTD were based on high 
doses of folic acid (≥5000 µg/d [20,22,46], ≥2500 µg/d [22,47] and ≥500 µg/d [48-50]), only 
2 women in our study population consumed as much as 5000 µg/d of supplemental folic acid, 
while only 10% consumed >500 µg/d and 16% consumed >400 µg/d. However, the 
Hungarian RCT, one of the biggest performed so far, did not find any effect of a high dosage 
of 800 µg/d of periconceptional folic acid supplementation on PTD [6]. Unfortunately, the 
folic acid dosage was not indicated in all of the studies [21,37]. 
The assessment of folate intake from supplementation alone or when studying populations 
with different dietary folate intakes are additional factors compromising comparability 
between studies. While recent US studies are performed against the background of mandatory 
folate fortification of food [21,43], other studies have examined supplementation effects in 
folate-deficient populations [46]. Few studies have assessed the effects of both dietary folate 
and folic acid supplementation separately [43] or combined [20,49,51], and adjustments for 
bioavailability are rare. In this Norwegian study population, only 3% of the participants 
reached the Nordic Nutrition Recommendation of 500 µg/d with their dietary folate intake, 
and 44% of the participants achieved the recommended level with their dietary folate and 
supplemental folic acid intake. After stratification for dietary folate intake, the early initiation 
of folic acid supplementation was significantly associated with spontaneous PTD in the 
subgroup of women with low but not high dietary folate intakes. There were no significant 
associations between high total folate intakes and PTD risk in the MoBa study population. 
In observational studies, confounding is always an issue when assessing the association of a 
single environmental factor with a complex outcome like PTD. For example, it is well 
established that women with high levels of education, privileged socioeconomic status and 
healthier overall diets are more likely to use supplements during pregnancy [52-54] and less 
likely to experience PTD than women without these characteristics. Some observational 
studies failed to adjust for these confounders, and the effect attributed to folic acid 
supplementation might in fact be confounded by overall health and lifestyle behaviors. While 
the strength of the significance was moderate, the association with the early onset of folic 
acid supplementation in the current study remained significant even after adjustment for 
maternal characteristics such as socioeconomic and life-style parameters as well as obstetric 
anamnesis. 
Associations with the early start of supplementation should be studied with particular caution. 
The early start of folic acid supplementation might partially identify a group of women with a 
history of adverse pregnancy outcomes who want to optimize conditions for their current 
pregnancy. As presented in Table 1, women who had previously experienced spontaneous 
abortions were more likely to initiate folic acid supplementation early in their subsequent 
pregnancies. However, the same association of the early initiation of folic acid 
supplementation and spontaneous PTD was found in women being pregnant the first time. 
Folic acid supplementation starting more than 8 weeks prior to conception might characterize 
women who planned a pregnancy but did not become pregnant during their first 2 cycles, thus 
constituting a subgroup of women with suboptimal fertility [37]. The same association of the 
early start of supplementation was found in the group of women that became pregnant within 
the first month. Women who choose to start early with folic acid supplementation might be 
distinguished by some other characteristic that could be the causal link to spontaneous 
preterm delivery so that we cannot exclude confounding. 
In addition to the amount of folic acid, the composition of supplements is another point of 
discussion. In some countries like Greece and Norway, commonly used supplements contain 
folic acid and/or iron only [20]. In other countries, folic acid is mainly consumed in the form 
of multivitamins, making it difficult to differentiate the effects of multivitamin use and folic 
acid supplementation [21,37,43,50]. Vitamins other than folic acid might explain the 
association between multivitamin use and PTD. Catov et al. found that in the Danish birth 
cohort, multivitamin use was associated with modestly decreased PTD rates, while there was 
no association with folic acid supplementation [39]. As seen from Figure 1, vitamin A 
consumption (as a proxy for multivitamin supplementation) differed considerably from folic 
acid supplementation. However, the MoBa FFQ allowed us to calculate folic acid separately 
from other supplements, and adjusting for vitamin A consumption did not change the results 
for preconceptional folic acid supplementation. 
Apart from the amount, timing and composition of folate exposure, differences in the 
definition of pregnancy outcomes hinder comparability. Most studies defined PTD as 
delivery at <37+0 weeks of gestation without indicating the range of gestational age. This 
information might be important, especially if the risk of early PTD is found to be associated 
with folate status, as suggested by this study and that of Bukowski et al. [21]. Although PTD 
is a heterogeneous pregnancy outcome with distinct etiologies for different subgroups [26], 
not all studies analyzed clearly defined subgroups such as spontaneous PTD 
[20,21,39,42,49,55]. 
Strengths and weaknesses 
With a sample size of 66,014 pregnancies, this was a well-powered study for investigating the 
association of folate intake and spontaneous PTD. Due to the large study sample, there were 
1,755 cases defined as spontaneous PTD and 334 and 1,421 cases in the subgroups of early 
and late spontaneous PTD, respectively. The estimation of the gestational length by the 
second-trimester ultrasounds and the definition of a clear PTD phenotype – spontaneous 
onset of delivery between 22+0 and 36+6 weeks of gestation - distinguish this study. 
The MoBa participation rate is 38.5%, and a demographic comparison with the MBRN in 
2002 showed that single women and women <25 y of age are underrepresented in MoBa. 
Regarding PTD (7.2% in MoBa and 7.7% in MBRN), the differences are minor, and even the 
sub-group composition is similar to the distribution in the total population, with spontaneous 
PTD accounting for 42% of all PTD [15]. Although the low participation in MoBa influences 
prevalence estimates somewhat, such non-representativeness does not appear to affect 
exposure–outcome associations [56,57]. 
The assessment of folate from both the diet and supplements is a major strength of this study. 
Although all dietary assessment methods have limitations, the MoBa FFQ has been 
extensively validated in a sub-population of 119 MoBa participants using a 4-day weighed 
food diary and biological markers in the blood and urine as reference measures [58]. The 
dietary supplement use was evaluated specifically. The total folate intake by the FFQ showed 
good agreement with the folate intake detailed by the food diary and was significantly 
reflected by the serum folate concentrations [33]. In a subsample of an earlier MoBa version 
(2934 singleton pregnancies), Nilsen et al. did not find any significant associations of dietary 
folate intake, folic acid supplementation or plasma folate with PTD. This study also reported 
good agreement between the folate intake (dietary and supplements) by the MoBa FFQ and 
plasma folate concentration (r = 0.44, CI: 0.41-0.47) [40]. As the relevant window of 
susceptibility for folate effects regarding pregnancy outcomes other than NTD is not yet 
known, the assessment of folate intake at different time points is a further strength of this 
study. The prospective design ensured that the women’s answers were not influenced by their 
knowledge of pregnancy outcomes. 
Conclusions 
The overall amount of dietary folate and supplemental folic acid intake (during the first half 
of pregnancy) in 66,014 singleton pregnancies from the Norwegian Mother and Child Cohort 
Study was not associated with decreased or increased risk of spontaneous PTD, at least not at 
the relatively low intake levels of dietary folate (median 157 µg/d corrected for bio-
availability, uncorrected 262 µg/d) and supplemental folic acid (median 143 µg/d) in this 
healthy study population. 
The initiation of folic acid supplementation more than 8 weeks prior to conception was 
associated with an increased risk for overall and early spontaneous PTD in both the overall 
analyses and in the strata of women with low dietary folate intake. 
Even if MoBa allows adjustment for a variety of confounders, the presence of residual 
confounding cannot be ruled out. Furthermore, our results require careful investigation 
regarding dosage and timing of folic acid supplementation, such as in the form of an RCT, 
before discussing a change of the current guidelines. 
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